148 related articles for article (PubMed ID: 20130438)
21. Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC).
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2012 Jan; 81(1):49-57. PubMed ID: 21396829
[TBL] [Abstract][Full Text] [Related]
22. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
McKeage MJ
Clin Lung Cancer; 2011 May; 12(3):143-7. PubMed ID: 21663855
[TBL] [Abstract][Full Text] [Related]
25. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
Floriani I; Garassino MC; Broggini M; Veronese S; Marsoni S; Marabese M; Farina G; Scanni A
J Clin Oncol; 2010 Sep; 28(27):e467; author reply e468. PubMed ID: 20585086
[No Abstract] [Full Text] [Related]
26. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.
Johnson ML; Patel JD
Semin Oncol; 2014 Feb; 41(1):93-100. PubMed ID: 24565583
[TBL] [Abstract][Full Text] [Related]
27. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
28. [Genomic approaches to tailored therapy in non-small cell lung cancer].
Song Y
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):889-90. PubMed ID: 19134403
[No Abstract] [Full Text] [Related]
29. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.
Langer CJ
Crit Rev Oncol Hematol; 2012 Jul; 83(1):130-44. PubMed ID: 22280915
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies in lung cancer.
Wang Y; Deng G; Liu X; Cho WC
Expert Opin Biol Ther; 2013 Feb; 13(2):209-26. PubMed ID: 23240766
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers.
Singh N; Bal A; Aggarwal AN; Das A; Behera D
Future Oncol; 2010 May; 6(5):741-67. PubMed ID: 20465389
[TBL] [Abstract][Full Text] [Related]
32. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.
Zalcman G; Bergot E; Creveuil C; Levallet G; Lechapt E
Curr Opin Oncol; 2011 Jan; 23(1):106-11. PubMed ID: 21076302
[TBL] [Abstract][Full Text] [Related]
33. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
34. Cancer vaccines for non-small-cell lung cancer.
Palma M; Choudhury A; Mellstedt H
Minerva Chir; 2009 Dec; 64(6):643-53. PubMed ID: 20029360
[TBL] [Abstract][Full Text] [Related]
35. Molecular predictive and prognostic markers in non-small-cell lung cancer.
Coate LE; John T; Tsao MS; Shepherd FA
Lancet Oncol; 2009 Oct; 10(10):1001-10. PubMed ID: 19796752
[TBL] [Abstract][Full Text] [Related]
36. Trial offers new model for drug development.
Cancer Discov; 2014 Mar; 4(3):266-7. PubMed ID: 24596189
[TBL] [Abstract][Full Text] [Related]
37. Management of advanced non-small cell lung cancer: current trends.
Haura EB
Curr Opin Pulm Med; 2002 Jul; 8(4):251-6. PubMed ID: 12055385
[TBL] [Abstract][Full Text] [Related]
38. Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment.
Nat Rev Drug Discov; 2010 Jun; 9(6):423. PubMed ID: 20514061
[No Abstract] [Full Text] [Related]
39. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery.
Printz C
Cancer; 2010 Jul; 116(14):3307-8. PubMed ID: 20602437
[No Abstract] [Full Text] [Related]
40. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
